Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Inclusion Criteria: * Males and females, 18 years or older. * Historical diagnosis of Gaucher disease with leukocyte GCD activity level ≤3 nmol/mg\*hr (≤30 % of the mean activity of the reference range) * Subjects who have not received enzyme replacement therapy (ERT) or substrate replacement therapy (SRT) in the past or patients who have not received ERT in the past twelve months * Body Mass Index (BMI) 19 to 25 kg/m2 (inclusive). * Non-smoking (by declaration) for a period of at least 6 months prior to screening visit. * Subjects in generally good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination. * Negative hepatitis B or hepatitis C serology tests at screening. * Ability to provide a written informed consent * Female subjects of child-bearing potential or male subjects with female partners of child-bearing potential must agree to use two methods of contraception, one of which must be a barrier method. Acceptable methods of contraception include hormonal products, intrauterine device, or male or female condoms. Exclusion Criteria: * Presence of any co-morbidity other than Gaucher Disease * Presence of any GIT disease or symptomatology suspected to be GIT related using a study specific GI questionnaire * Subjects with any history of allergic response to drugs or other allergies deemed clinically significant or exclusionary for the study, including known food allergies * History of alcohol or drug abuse * Subjects who donated blood in the three months, or received blood or plasma derivatives in the six months, preceding study drug administration. * Use of any investigational drug at screening or within 3 months of dosing. * Subjects with an inability to communicate well with the investigators and study staff (i.e., language problem, poor mental development or impaired cerebral function). * Subjects who are non-cooperative or unwilling to sign the consent form. * Pregnant or nursing or planning to be pregnant during the study period. * Have used any medication (excluding paracetamol), within 7 days of study drug administration including laxatives or other drugs, teas or food additives known to be used to treat constipation or diarrhea. * Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the investigator would interfere with the subject's compliance with the requirements of the study.